#USA #Seattle #Jazz Pharmaceuticals #Xywav #SLEEP 2025

Introduction to SLEEP 2025 Presentation

Jazz Pharmaceuticals, a leading player in the biopharmaceutical sector, is preparing to make a significant impact at the upcoming SLEEP 2025 conference, scheduled for June 8-11, 2025, in Seattle. The company will present a total of nineteen abstracts, featuring eleven late-breaking studies, that explore the comprehensive treatment benefits of their groundbreaking medication, Xywav®. This medication is a low-sodium formulation designed to address serious sleep disorders such as narcolepsy and idiopathic hypersomnia (IH).

Research Highlights

Among the key presentations will be dual late-breaking poster and oral presentations showcasing Phase 4 clinical trial data evaluating the efficacy of Xywav in patients suffering from narcolepsy and IH. Notably, the first interim results from the XYLO trial will be unveiled, which represented the effects of switching from a high-sodium oxybate oral solution to Xywav on patients' blood pressure.

In addition to the XYLO trial, findings from the DUET trial will be highlighted, detailing several sleep parameters influenced by Xywav, with specific emphasis on polysomnography (PSG) outcomes in adults with IH. The efficacy and safety of Xywav were evaluated in a group of narcolepsy patients, many of whom had their doses optimized above the standard maximum of 9 grams per night, a dosage that shows promise for managing these complex conditions.

A Holistic Approach to Patient Care

Dr. Kelvin Tan, Chief Medical Affairs Officer at Jazz Pharmaceuticals, commented, "Our commitment to supporting patients with sleep disorders extends beyond medication. We prioritize a holistic approach that encompasses a broader understanding of their health needs. The extensive data we present at SLEEP 2025 reinforces our dedication to developing innovative therapies like Xywav, particularly as we address cardiovascular risks linked to sodium intake among our patients."

Important Presentations and Findings

Among the important findings that attendees can expect at SLEEP 2025 are:

• - Two late-breaking poster presentations from the CHIME study, evaluating the real-world effectiveness and treatment adherence among adults with narcolepsy and IH taking Xywav.
• - A detailed claims analysis on the prevalence and impairing effects of sleep inertia in individuals diagnosed with IH.
• - Results from the INTREPID study, a retrospective analysis using Optum Market Clarity data from 2007-2023 to explore treatment patterns in narcolepsy and IH patients following the approval of Xywav.
• - Findings from the DUET trial that reveal improvements in sleep architecture, demonstrating Xywav's efficacy in enhancing sleep quality for narcolepsy and IH patients.
• - Interim results from the LYRICAL study, which investigates real-world efficacy and patient-reported outcomes, affirming symptom relief and high treatment satisfaction levels.

Clinical Significance of Xywav

Xywav is the only low-sodium oxybate FDA-approved for both cataplexy and excessive daytime sleepiness (EDS) in patients over 7 years old with narcolepsy. The unique formulation includes calcium, magnesium, and potassium alongside sodium oxybates, providing significant cardiovascular safety advantages over existing treatments. By delivering 92% less sodium, it stands as a pivotal alternative for patients concerned about sodium intake.
Jazz's research is not just about numbers; it's also about lives. Adequate management of narcolepsy and IH improves the quality of life among those affected, making these innovations critical in the field of sleep medicine.

Closing Remarks

As Jazz Pharmaceuticals gears up to share these vital findings at SLEEP 2025, their ongoing commitment to patient health and innovative research is evident. For additional information and to access the full list of presentations, the conference attendees are encouraged to visit sleepmeeting.org.

In conclusion, Xywav® continues to demonstrate its potential as a transformative therapy, addressing complex sleep disorders while considering patient safety and quality of life. With critical presentations forthcoming, Jazz Pharmaceuticals is poised to maintain its leadership role in advancing treatments that significantly benefit patients across the globe.